-
Clinical, Cosmetic and Investigational Dermatology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Botulinum toxin type A for the management of glabellar rhytids
(855) Article views
Authors: Anne Marie Tremaine, Jerry L McCullough
Published Date April 2010 , Volume 2010:3 Pages 15 - 23 DOI 10.2147/CCID.S6492
Anne Marie Tremaine, Jerry L McCullough
Department of Dermatology, University of California, Irvine, CA, USA
Abstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process. Botulinum toxin type A injections are the most commonly used nonsurgical cosmetic procedures in the United States. There has been research spanning over two decades dedicated to safety, efficacy, dosing, and complications of botulinum toxin type A. There are now two Food and Drug Administration (FDA) approved botulinum toxin type A options in the United States: Botox® and Dysport™, with new advances being made in the field.
Keywords: botulinum toxin type A, glabella, Botox, Dysport, complications, dosing
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
